Abstract
Background: Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [99mTc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer.
Methods: Twelve women (42–71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter, .007 μm) or .2 μm of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator.
Results: The receptor-binding agent, Lymphoseek, exhibited a significantly (P = .0025) faster injection site clearance (rate, .255 ± .147/hour; fTcSC rate, .014 ± .018/hour); the mean Lymphoseek clearance half-time was 2.72 ± 1.57 hours compared with 49.5 ± 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range, .02%–1.12%; mean, .55% ± .43%) and fTcSC (range, .00%–1.93%; mean, .65% ± .63%) did not differ (P = .75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin.
Conclusions: The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.
Similar content being viewed by others
REFERENCES
Stern H, McAfee J, Subramanian G. Preparation, distribution and utilization of technetium-99m sulfur colloid. J Nucl Med 1966; 7: 655–75.
Larson S, Nelp W. Radiopharmacology of a simplified technetium-99m colloid preparation for photoscanning. J Nucl Med 1966; 7: 817–26.
Sacks GA, Sandler MP, Born ML. Lymphoscintigraphy as an adjunctive procedure in the perioperative assessment of patients undergoing microlymphaticovenous anastomoses. Clin Nucl Med 1983; 8: 309–11.
Hung JC, Wiseman GA, Wahner HW, et al. Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy. J Nucl Med 1995; 36: 1895–901.
Uren R, Thompson JF, Howman-Giles RB. Lymphatic Drainage of the Skin and Breast. Singapore: Harwood Academic Publishers, 1999.
Nieweg OE, Essner R, Reintgen DS, Thompson JF, eds. Lymphatic Mapping and Probe Applications in Oncology. New York: Marcel Dekker, 2000.
Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001; 42: 1198–215.
Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: [99mTc]DTPA-mannosyl-dextran. J Nucl Med 2001; 42: 951–9.
Steer CJ, Ashwell G. Receptor-Mediated Endocytosis: Mechanisms, Biologic Function, and Molecular Properties. 2nd ed. Philadelphia: WB Saunders, 1990.
Hoh CK, Wallace AM, Vera DR. Preclinical studies of [99mTc]- DPTA-mannosyl-dextran. Nucl Med Biol 2003; 30: 457–64.
Robbins PJ. Chromatography of Technetium-99m Radiopharmaceuticals—A Practical Guide. New York: The Society of Nuclear Medicine, 1984.
Bevington PR. Data Reduction and Error Analysis for the Physical Sciences. New York: McGraw-Hill, 1969.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Developing Medical Imaging Drugs and Biological Products. Rockville, MD: US Department of Health and Human Services, 2000.
Gulec S, Moffat FL, Carroll RG, et al. Sentinel lymph node localization in early breast cancer. J Nucl Med 1998; 39: 1388–93.
McMasters KM, Wong SL, Martin RCG II, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233: 676–87.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical re-section and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335–9.
Vera DR, Krohn KA, Stadalnik RC, Scheibe PO. Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding. J Nucl Med 1984; 25: 779–87.
Veronesi U, Paganelli G, Galemberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864–7.
Albertini J, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy and lymphatic mapping of patients with breast cancer. JAMA 1996; 276: 1818–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wallace, A.M., Hoh, C.K., Vera, D.R. et al. Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection. Ann Surg Oncol 10, 531–538 (2003). https://doi.org/10.1245/ASO.2003.07.012
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2003.07.012